Quality Overall Summary: 40 Pages That Frame Module 3

The Quality Overall Summary is section 2.3 of the CTD. It presents the quality information in Module 3 in a form a reviewer can assess quickly: the scope of the data, the control strategy, and the residual risk.

It is the first quality document a reviewer reads, and for parts of the application it may be the only one they read closely.

The page limit is the design

The QOS should be no more than 40 pages of text, excluding tables and figures. Biotechnology products, including gene therapies, may run longer but should not exceed 80 pages.

That constraint is the whole point. Module 3 can be thousands of pages. Forty pages forces a decision about what actually matters, and the decision is yours rather than the reviewer's.

What belongs in it

It follows Module 3's structure: drug substance, then drug product, then the sections that follow.

• Drug substance: general information, manufacture, characterisation, control, reference standards, container closure, stability.
• Drug product: description and composition, pharmaceutical development, manufacture, control of excipients, control of drug product, reference standards, container closure, stability.

And crucially, the control strategy: how the combination of specifications, in-process controls and process understanding assures quality, and what risk remains after all of it.

The mistake

Writing it as a summary.

A QOS that compresses Module 3 without interpreting it makes the reviewer do the synthesis anyway, and it wastes the one chance you have to frame the data. FDA's own commentary on the QOS is about putting the pieces together, not about shortening them.

What a good QOS does that a summary does not:

• States the control strategy as an argument, rather than listing controls.
• Says where the risk is and why the controls address it. A QOS with no residual risk anywhere is not credible.
• Explains the development history that led to the current process, so the reviewer understands why it looks as it does.
• Is consistent with Module 3. Every number in the QOS appears somewhere in Module 3, and a discrepancy between them is a question, sometimes a deficiency.

Where it also appears

A QOS is required beyond a new application. It appears in the CEP procedure at EDQM, and several regions publish their own QOS templates. Health Canada has a long-standing template of its own.

A QOS also has to be maintained. A post-approval change that alters Module 3 usually alters the QOS, and an out-of-date QOS is one of the easier inconsistencies for a reviewer to find.